

June 26, 2019

To,  
The Manager  
Listing Department,  
**The National Stock Exchange of India Limited**  
Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400051

Dear Sir/Madam,

**Trading Symbol: ZOTA**

**Sub: Product Registration in Uzbekistan**

**Ref.: Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Pursuant to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 this is to inform you that we, Zota Health Care Limited (the "Company") have received product registration licenses for below mentioned 3 products from Uzbekistan.

Sr. No.	Name of Product	Therapeutic Category
1	LIVOTA – 250 (Tablet – LEVOFLOXACIN 250 mg)	Antibiotic
2	LIVOTA – 500 (Tablet – LEVOFLOXACIN 500 mg)	Antibiotic
3	LIVOTA – 750 (Tablet – LEVOFLOXACIN 750 mg)	Antibiotic

We have received licenses for the aforementioned products for the validity period of five years, license for the products are also renewable. Company shall start exporting these products in Uzbekistan very soon.

This is for your information and record.


Thanking you,

Yours faithfully,

For Zota Health Care Limited



**Ashvin Variya**  
(Company Secretary & Compliance Officer)  
Place: Surat



**Registered Office :**

Zota House, 2/896, Hira Modi Street,  
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601  
Email: info@zotahealthcare.com  
Web : www.zotahealthcare.com

**Plant :**

Plot no. 169, Surat Special Economic Zone,  
Nr. Sachin Railway Station, Sachin,  
Surat - 394 230 (Guj.) India  
Ph: +91 261 2397122